Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 1.00 |
| ▸ | ENPP1 | P22413 | 4/20 | 1.00 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 1.00 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.98 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.98 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.98 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.98 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195865 | 1.00 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL18089710 | 1.00 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL29381860 | 0.99 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL10120953 | 0.99 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL375601 | 0.99 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL375602 | 0.99 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL12216627 | 0.96 | P2RY1 (0.95) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL18089712 | 0.94 | P2RY1 (0.89) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL18089797 | 0.93 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL8862410 | 0.93 | P2RY1 (0.86) | P2RY1ENPP1P2RY12P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230324392-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | US | claimed |
| EP-4240339-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | Fred Hutchinson Cancer Center (US) | 2023-09-13 | — | — | EP | claimed |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-24 | — | — | US | claimed |
| EP-4208572-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | Memorial Sloan Kettering Cancer Center (US) | 2023-07-12 | — | — | EP | claimed |
| WO-2022098776-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022051420-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-10 | — | — | WO | claimed |
| US-8895259-B2 | Method for determination of platelet function under flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2014-11-25 | — | — | US | claimed |
| US-7960131-B2 | Functional genomic pore assay for mixed cell populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | claimed |
| EP-1850135-B1 | Method for determining the thrombocyte function and flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2010-11-03 | — | — | EP | claimed |
| US-7560243-B2 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-14 | — | — | US | claimed |
| US-20090053204-A1 | Functional Genomic Pore Assay For Mixed Cell Populations | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | US | claimed |
| US-20070254324-A1 | Method for determination of platelet function under flow conditions | DADE BEHRING MARBURG GMBH | 2007-11-01 | — | — | US | claimed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20040253650-A1 | White blood cell functional assay | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-16 | — | — | US | claimed |
| US-20030059878-A1 | Novel purinoceptor and gene thereof | TANABE SEIYAKU CO., LTD (JP) | 2003-03-27 | — | — | US | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2002004955-A2 | ASSAY METHOD AND SYSTEM FOR IDENTIFICATION OF P2Y RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001085722-A1 | HETEROBICYCLIC SULFONAMIDES AND THEIR USE AS PLATELET ADP RECEPTOR INHIBITORS | COR THERAPEUTICS, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001057037-A1 | PLATELET ADP RECEPTOR INHIBITORS | COR THERAPEUTICS, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053612-A1 | Nucleotide regulation of immune responses | NT5C2, ENTPD5, ENTPD1 | P2RY1 7/4885ENPP1 44/4885P2RY12 23/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885ENPP1 1887/4885P2RY12 2119/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | P2RY1 4333/4885ENPP1 1862/4885P2RY12 2839/4885 |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | BMP4, P2RY2, GPR39 | P2RY1 6/4885ENPP1 351/4885P2RY12 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.